Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.69 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | KIF11 | P52732 | 3/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.47 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3722991 | 0.98 | AGXT (0.67) | AGXTMAOBKIF11TAAR1BACE1 | |
| SCHEMBL3727416 | 0.87 | MAOB (0.61) | AGXTMAOBKIF11TAAR1BACE1 | |
| SCHEMBL17048549 | 0.86 | MAOB (0.51) | AGXTMAOBTAAR1BACE1SYK | |
| SCHEMBL2091314 | 0.85 | MAOB (0.68) | AGXTMAOBKIF11TAAR1BACE1 | |
| SCHEMBL16894228 | 0.84 | MAOB (0.76) | AGXTMAOBKIF11TAAR1BACE1 | |
| Hydrochloric Acid SCHEMBL6180176 | 0.83 | MAOB (0.71) | AGXTMAOBKIF11TAAR1BACE1 | |
| SCHEMBL3794460 | 0.82 | TAAR1 (0.70) | AGXTMAOBTAAR1 | |
| SCHEMBL15125581 | 0.82 | F9 (0.52) | AGXTKIF11TAAR1DHODH | |
| SCHEMBL30542002 | 0.82 | AGXT (0.64) | AGXTMAOBKIF11PTPN5CASR | |
| SCHEMBL3522621 | 0.82 | AGXT (0.64) | AGXTMAOBKIF11PTPN5CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | claimed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | claimed |
| EP-2900642-B1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-02-28 | — | — | EP | disclosed |
| EP-2900642-B1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-9580411-B2 | Substituted sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580411-B2 | Substituted sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580411-B2 | Substituted sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9409864-B2 | Sulfonamide TRPA1 receptor antagonists | ARIO PHARMA LIMITED (GB) | 2016-08-09 | — | — | US | disclosed |
| US-20160024009-A1 | Novel Sulfonamide TRPA1 Receptor Antagonists | ARIO PHARMA LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| EP-2964615-A1 | NOVEL SULFONAMIDE TRPA1 RECEPTOR ANTAGONISTS | Ario Pharma Limited (GB) | 2016-01-13 | — | — | EP | disclosed |
| EP-2900642-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | disclosed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
| EP-1874753-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113432-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
| US-5278191-A | Nervous system disorders | G. D. SEARLE & CO. (US) | 1994-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024009-A1 | Novel Sulfonamide TRPA1 Receptor Antagonists | TRPA1, TRPV1, TRPV2 | AGXT 2908/4885MAOB 3798/4885KIF11 4145/4885 |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | AGXT 2142/4885MAOB 2787/4885KIF11 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.